Back to News
Market Impact: 0.15

US fertility rates drop to record low in 2025 as births fall

Economic DataHealthcare & Biotech
US fertility rates drop to record low in 2025 as births fall

The U.S. recorded roughly 3.6 million births in 2025, a 1% decline year-over-year, and the general fertility rate fell 1% to 53.1 births per 1,000 women aged 15-44 (down ~23% since 2007). Declines were concentrated among women under 30 (age 25-29 down ~4.4%), while rates rose modestly for ages 30-34 (+2.7%); teen rates fell sharply (18-19 down 7%, 15-17 down 11%). Data are provisional from the CDC/NCHS based on 99.95% of birth records processed as of Feb. 3, 2026, indicating a persistent, multi-decade downward trend rather than a transitory blip.

Analysis

Demographic shifts that reduce future cohort sizes change revenue trajectories in durable and non-durable consumer categories unevenly: per-household spend on higher-value parenting services (IVF, premium childcare, specialized pediatric care) can rise even as volumes for mass-market baby staples compress. That bifurcation creates a margin arbitrage opportunity for niche providers with pricing power (specialist clinics, fertility benefit managers) versus scale-dependent consumer staples that rely on unit growth to hide margin pressure. On a macro level, a structurally slower supply of new labor entrants amplifies medium-term wage pressure in low/mid-skill services (childcare, hospitality, retail) and increases employer demand for automation and outsourcing solutions; this feeds through to higher capex for automation vendors and to tighter margins for labor-intensive operators. Fiscal dynamics also shift: with a higher retiree-to-worker ratio, expect elevated political pressure for immigration, family subsidies, or both — any of which could materially alter growth assumptions for affected sectors within 12–36 months. Real assets and healthcare services are second-order beneficiaries: demand for geriatric care, assisted living, and certain outpatient specialties should rise per capita, improving occupancy and pricing power for specialized REITs and healthcare operators even as K‑12 and pediatric-driven demand softens. Conversely, incumbents in broad baby-centric consumer staples and entry-level homebuilders face multi-year unit volume headwinds; their defensive dividend narratives will be tested if revenue bases shrink rather than merely reprice. Key policy and cyclical catalysts to watch are (1) expansion of public or employer-funded fertility benefits, (2) immigration/tax policy changes, and (3) cyclical consumer confidence that could either accelerate or delay household formation — each can flip sector winners/losers in a 6–24 month window and should be used as triggers for position scaling.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Key Decisions for Investors

  • Long Progyny (PGNY) 12–18 month call spread (buy Aug 2026 25C / sell Aug 2026 40C) — directional play on premium fertility services and employer benefit adoption. Target +60–100% if revenue per case and employer penetration accelerate; max loss = premium paid. Scale on pullbacks after earnings or a large employer benefit win announcement.
  • Long CooperCompanies (COO) 6–12 month buy (add on weakness) — device exposure to IVF/ART procedures and female health diagnostics. Risk/reward: 25–35% upside if procedure volumes stabilize or recover vs ~15% downside in a broader selloff; hedge with sector ETF (XLV) if market volatility rises.
  • Pair trade (6–24 months): Long Ventas (VTR) or Welltower (WELL) 5–10% position / Short Procter & Gamble (PG) equal notional — thematic long senior housing REITs (aging-driven demand, pricing power) vs short mass-market baby staples (unit decline pressure). Expect divergence of 10–20% under base case; monitor rate volatility as REITs are rate sensitive — hedge duration with shorter-dated Treasuries if real yields spike.
  • Short Kimberly-Clark (KMB) 9–12 month puts (sell a covered call or buy puts for directional) sized to portfolio risk — target capture of unit volume contraction in diapers/tissues as secular cohort shrinkage pressures top line. Catalysts: quarterly organic sales weakness; risk is modest defensible pricing power and buybacks reducing volatility.